The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Open accessAbstract
Importance: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti-epidermal growth factor receptor-based regimen might be efficacious. Recent data suggest the role of liquid biopsy as a tool to track molecular events in circulating tumor DNA (ctDNA). Objective: To prospectively assess the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type mCRC who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy. Design, Setting, and Participants: Multicenter phase 2 single-arm trial conducted from January 7, 2015, to June 19, 2017. Liquid biopsies for analysis of ctDNA were collected at baseline. Main eligibility criteria included RAS and BRAF wild-type status on tissue samples; prior first-line irinotecan- and cetuximab-based regimen with at least partial response, progression-free survival of at least 6 months with first-line therapy, and progression within 4 weeks after last dose of cetuximab; and prior second-line oxaliplatin- and bevacizumab-based treatment. Interventions: Biweekly cetuximab, 500 mg/m2, plus irinotecan, 180 mg/m2. Main Outcomes and Measures: Overall response rate according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival and overall survival and, as an exploratory analysis, RAS mutations in ctDNA. Results: Twenty-eight patients (9 women and 19 men; median age, 69 years [range, 45-79 years]) were enrolled. Six partial responses (4 confirmed) and 9 disease stabilizations were reported (response rate, 21%; 95% CI, 10%-40%; disease control rate, 54%; 95% CI, 36%-70%). Primary end point was met because lower limit of 95% CI of response rate was higher than 5%. RAS mutations were found in ctDNA collected at rechallenge baseline in 12 of 25 evaluable patients (48%). No RAS mutations were detected in samples from patients who achieved confirmed partial response. Patients with RAS wild-type ctDNA had significantly longer progression-free survival than those with RAS mutated ctDNA (median progression-free survival, 4.0 vs 1.9 months; hazard ratio, 0.44; 95% CI, 0.18-0.98; P = .03). Conclusions and Relevance: This is the first prospective demonstration that a rechallenge strategy with cetuximab and irinotecan may be active in patients with RAS and BRAF wild-type mCRC with acquired resistance to first-line irinotecan- and cetuximab-based therapy. The evaluation of RAS mutational status on ctDNA might be helpful in selecting candidate patients. Trial Registration: ClinicalTrials.gov Identifier: NCT02296203.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BRAF mutation is a powerful biomarker of poor prognosis for mCRC patients receiving anti-EGFR mAbs [80, 91, 92].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“Objective response ratea (95% CI) 6 (21) (10-40)”
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citationOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citationCOSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922
Research works printed but not linked: 3
- Meazza, 2016, AKT1 and BRAF mutations in pediatric aggressive fibromatosis., Cancer Med, 5, 1204, 10.1002/cam4.2016.5.issue-6 · DOI
- dbSNP: short genetic variations. Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine. https://www.ncbi.nlm.nih.gov/SNP/. Accessed June 15, 2018.
- ClinVar. https://www.ncbi.nlm.nih.gov/clinvar/. Accessed June 15, 2018.
Cited by
Sorted by citations
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,737
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Circulating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 556
Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214963 · Cited by 467
Self-citationEng, C., Yoshino, T., Ruíz‐García, E., Mostafa, N., Cann, C., O’Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 508
Self-citationTreatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Bianchi, A. S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 337
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 310
ctDNA as a cancer biomarker: A broad overview
Pessoa, L. S., Heringer, M., & Ferrer, V. P. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103109 · Cited by 311
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02615 · Cited by 309
Bianchi, A. S., Pietrantonio, F., Lonardi, S., Mussolin, B., Rua, F., Crisafulli, G., Bartolini, A., Fenocchio, E., Amatu, A., Manca, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01886-0 · Cited by 287
Self-citationCirculating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Bartolomucci, A., de Nóbrega, M., Ferrier, S. T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00876-y · Cited by 301
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Precision oncology in metastatic colorectal cancer — from biology to medicine
Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 244
Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178
Peng, Y., Mei, W., Ma, K., & Zeng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763790 · Cited by 167
Therapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 151
Rolfo, C. D., Cardona, A. F., Cristofanilli, M., Paz-Ares, L. G., Díaz‐Mochon, J. J., Durán, I., Raez, L. E., Russo, A., Lorente, J. A., Malapelle, U., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102978 · Cited by 143
Current Targeted Therapy for Metastatic Colorectal Cancer
Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 138
Recent developments in immunotherapy for gastrointestinal tract cancers
Chong, X., Madeti, Y., Cai, J., Li, W., Cong, L., Lu, J., Mo, L., Liu, H., He, S., Yu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01578-x · Cited by 132
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 124
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
Pinzani, P., D’Argenio, V., Re, M. D., Pellegrini, C., Cucchiara, F., Salvianti, F., & Galbiati, S. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1685 · Cited by 123
Lan, H., Liu, Y., Liu, J., Wang, X., Guan, Z., Du, J., & Jin, K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00961 · Cited by 112
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer
Bando, H., Nakamura, Y., Taniguchi, H., Shiozawa, M., Yasui, H., Esaki, T., Kagawa, Y., Denda, T., Satoh, T., Yamazaki, K., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00535 · Cited by 111
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1569 · Cited by 116
Russo, A. D., Incorvaia, L., Re, M. D., Malapelle, U., Capoluongo, E., Gristina, V., Castiglia, M., Danesi, R., Fassan, M., Giuffrè, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100164 · Cited by 106
Self-citationLiquid biopsies to monitor and direct cancer treatment in colorectal cancer
Mauri, G., Vitiello, P. P., Sogari, A., Crisafulli, G., Bianchi, A. S., Marsoni, S., Siena, S., & Bardelli, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01769-8 · Cited by 108
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 106
Self-citationThe Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
Reece, M. M., Saluja, H., Hollington, P., Karapetis, C. S., Vatandoust, S., Young, G. P., & Symonds, E. L. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01118 · Cited by 95
Mauri, G., Pizzutilo, E. G., Amatu, A., Bencardino, K. B., Palmeri, L., Bonazzina, E. F., Tosi, F., Stella, G. C., Burrafato, G., Scaglione, F., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.006 · Cited by 90
How we treat metastatic colorectal cancer
Falco, V. D., Napolitano, S., Roselló, S., Huerta, M., Cervantes, A. M. R., Ciardiello, F., & Troiani, T. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000813 · Cited by 94
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Napolitano, S., Martini, G., Ciardiello, D., Tufo, S. D., Martinelli, E., Troiani, T., & Ciardiello, F. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00479-x · Cited by 94
A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers
Cheng, R., Li, F., Zhang, M., Xia, X., Wu, J., Gao, X., Zhou, H., Zhang, Z., Huang, N., Yang, X., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00726-7 · Cited by 87
Yoshino, T., Cervantes, A. M. R., Bando, H., Martinelli, E., Oki, E., Xu, R., Mulansari, N. A., Babu, K. G., Lee, M. A., Tan, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101558 · Cited by 91
Parseghian, C. M., Sun, R., Woods, M. N., Napolitano, S., Lee, H. M., Alshenaifi, J. Y., Willis, J. A., Nunez, S., Raghav, K. P. S., Morris, V. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01423 · Cited by 84
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taïeb, J., Jung, A., Bianchi, A. S., Peeters, M., Seligmann, J. F., Zaanan, A., Burdon, P., Montagut, C. O., & Laurent‐Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 78
Jensen, L. H., Rogatto, S. R., Lindebjerg, J., Havelund, B. M., Abildgaard, C., do Canto, L. M., Vagn-Hansen, C., Dam, C., Rafaelsen, S. R., & Hansen, T. F. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02683-4 · Cited by 74
Cremolini, C., Chalabi, M., Élez, E., Fassan, M., Gelli, M., Goèré, D., Modest, D. P., Viladot, C. M., Osterlund, P. J., Ricke, J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.03.005 · Cited by 89
Self-citationTopham, J. T., O'Callaghan, C. J., Feilotter, H., Kennecke, H. F., Lee, Y. S., Li, W., Banks, K. C., Quinn, K., Renouf, D. J., Jonker, D. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00364 · Cited by 70
Mitani, S., & Kawakami, H. (2020) · Cancers · doi:10.3390/cancers12020400 · Cited by 69
Yan, W., Qiu, L., Yang, M., Xu, A., Ma, M., Yuan, Q., Ma, X., Liang, W., Li, X., & Lu, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216263 · Cited by 63
Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., García, A., Alcaráz, A., Vega, S., Bueno, S., Tabernero, J. M., et al. (2023) · Cancers · doi:10.3390/cancers15164020 · Cited by 64
Clinical application of circulating tumour DNA in colorectal cancer
Loft, M., To, Y. H., Gibbs, P., & Tie, J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00146-2 · Cited by 67
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer
Ciardiello, D., Martinelli, E., Troiani, T., Mauri, G., Rossini, D., Martini, G., Napolitano, S., Famiglietti, V., Tufo, S. D., Masi, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5635 · Cited by 64
Self-citationCombined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
Baraibar, I., Mirallas, O., Gonzalez, N. S., Ros, J., Salvà, F., Tabernero, J. M., & Élez, E. (2021) · Cancers · doi:10.3390/cancers13246311 · Cited by 61
Napolitano, S., Falco, V. D., Martini, G., Ciardiello, D., Martinelli, E., Corte, C. M. D., Esposito, L., Famiglietti, V., Liello, A. D., Avallone, A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0655 · Cited by 60
Self-citationUpdate in version 2021 of CSCO guidelines for colorectal cancer from version 2020
Dong, C., Ding, Y., Weng, S., Li, G., Huang, Y., Hu, H., Zhang, Z., Zhang, S., & Yuan, Y. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.02 · Cited by 60
Martini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 59
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 58
Self-citationResistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 57
Duffy, M. J., & Crown, J. P. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac121 · Cited by 55
Klein‐Scory, S., Wahner, I., Maslova, M., Al‐Sewaidi, Y., Pohl, M., Mika, T., Ladigan, S., Schroers, R., & Baraniskin, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01115 · Cited by 52
Current and Emerging Biomarkers in Metastatic Colorectal Cancer
Lee, M. K. C., & Loree, J. M. (2019) · Current Oncology · doi:10.3747/co.26.5719 · Cited by 50
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Martini, G., Dienstmann, R., Ros, J., Baraibar, I., Cuadra‐Urteaga, J. L., Salvà, F., Ciardiello, D., Mulet-Margalef, N., Argilés, G., Tabernero, J. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936089 · Cited by 57
Sunakawa, Y., Nakamura, M., Ishizaki, M., Kataoka, M., Satake, H., Kitazono, M., Yanagisawa, H., Kawamoto, Y., Kuramochi, H., Ohori, H., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00109 · Cited by 54
Güven, D. C., Şahin, T. K., Yildirim, H. Ç., Aktepe, O. H., Dızdar, Ö., & Yalçın, Ş. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103528 · Cited by 50
Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Cohen, R., Pudlarz, T., Delattre, J.-F., Colle, R., & André, T. (2020) · Cancers · doi:10.3390/cancers12092350 · Cited by 49
Masuishi, T., Tsuji, A., Kotaka, M., Nakamura, M., Kochi, M., Takagane, A., Shimada, K., Denda, T., Segawa, Y., Tanioka, H., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01042-w · Cited by 50
Anti‐angiogenesis in colorectal cancer therapy
Yang, Z., Zhang, X., Bai, X., Xi, X., Liu, W., & Zhong, W. (2024) · Cancer Science · doi:10.1111/cas.16063 · Cited by 50
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 50
Johnson, D., Chee, C. E., Wong, W., Lam, R. C. T., Tan, I. B. H., & Ma, B. B. Y. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102700 · Cited by 48
Callesen, L. B., Hamfjord, J., Boysen, A. K., Pallisgaard, N., Guren, T. K., Kure, E. H., & Spindler, K. G. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01816-4 · Cited by 43
Liquid biopsies across the cancer care continuum
Landon, B. V., Annapragada, A. V., Niknafs, N., Velculescu, V. E., & Anagnostou, V. (2025) · Nature Medicine · doi:10.1038/s41591-025-04093-9 · Cited by 55
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
Malapelle, U., Passiglia, F., Cremolini, C., Reale, M. L., Pepe, F., Pisapia, P., Avallone, A., Cortinovis, D. L., Stefano, A. D., Fassan, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.015 · Cited by 43
Self-citationYao, Y., Wang, Y., Chen, L., Tian, Z., Yang, G., Wang, R., Wang, C., Wu, Q., Wu, Y., Gao, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00908-0 · Cited by 44
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 44
Moati, É., Blons, H., Taly, V., Garlan, F., Renault, S., Pietrasz, D., Didelot, A., Garrigou, S., Saint, A., Pernot, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32657 · Cited by 43
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
Self-citationUnveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 41
Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 47
Self-citationRaghav, K. P. S., Ou, F., Venook, A. P., Innocenti, F., Sun, R., Lenz, H., & Kopetz, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00365 · Cited by 40
Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 40
Decoding the Dynamics of Circulating Tumor DNA in Liquid Biopsies
Turabi, K. S., Klute, K. A., & Radhakrishnan, P. (2024) · Cancers · doi:10.3390/cancers16132432 · Cited by 40
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Lai, E., Liscia, N., Donisi, C., Mariani, S., Tolu, S., Pretta, A., Persano, M., Pinna, G., Balconi, F., Pireddu, A., et al. (2020) · Cancers · doi:10.3390/cancers12051214 · Cited by 37
Napolitano, S., Ciardiello, D., Falco, V. D., Martini, G., Martinelli, E., Corte, C. M. D., Esposito, L., Famiglietti, V., Liello, A. D., Avallone, A., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34632 · Cited by 38
Hamid, M. A., Pammer, L. M., Oberparleiter, S., Günther, M., Amann, A., Gruber, R., Mair, A., Nocera, F. I., Ormanns, S., Zimmer, K., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00892-y · Cited by 41
Manca, P., Corallo, S., Lonardi, S., Fucà, G., Busico, A., Leone, A. G., Corti, F., Antoniotti, C., Procaccio, L., Smiroldo, V., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01591-8 · Cited by 38
Self-citationJia, L.-L., Zhao, J.-X., Zhao, L., Tian, J., & Huang, G. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110640 · Cited by 37
Napolitano, S., Martini, G., Ciardiello, D., Di Maio, M., Normanno, N., Avallone, A., Martinelli, E., Maiello, E., Troiani, T., & Ciardiello, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.940523 · Cited by 35
Circulating tumor cells in colorectal cancer in the era of precision medicine
Hu, M., Wang, Z., Wu, Z., Ding, P., Pei, R., Wang, Q., & Xing, C. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02162-3 · Cited by 38
Boccaccino, A., Borelli, B., Intini, R., Antista, M., Bensi, M., Rossini, D., Passardi, A., Tamberi, S., Giampieri, R., Antonuzzo, L., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100506 · Cited by 38
Self-citationRecent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Wang, W., & Tse‐Dinh, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190401113350 · Cited by 35
Circulating tumor DNA in colorectal cancer: opportunities and challenges.
Bi, F., Wang, Q., Dong, Q., Wang, Y., Zhang, L., & Zhang, J. (2020) · PubMed Central · Cited by 35
Patelli, G., Vaghi, C., Tosi, F., Mauri, G., Amatu, A., Massihnia, D., Ghezzi, S., Bonazzina, E. F., Bencardino, K. B., Cerea, G., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00795-5 · Cited by 39
Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
Ciardiello, D., Martini, G., Famiglietti, V., Napolitano, S., Falco, V. D., Troiani, T., Latiano, T. P., Ros, J., Élez, E., Vitiello, P. P., et al. (2021) · Cancers · doi:10.3390/cancers13081941 · Cited by 36
Osumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 38
Xu, Y., Zhao, J., Ni, X., Wang, W., Hu, W., & Wu, C. (2021) · Epigenomics · doi:10.2217/epi-2021-0130 · Cited by 35
Battaglin, F., Puccini, A., Djaballah, S. A., & Lenz, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s186042 · Cited by 36
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 36
Nakajima, H., Kotani, D., Bando, H., Kato, T., Oki, E., Shinozaki, E., Sunakawa, Y., Yamazaki, K., Yuki, S., Nakamura, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08395-2 · Cited by 35
Current therapy of advanced colorectal cancer according to RAS/RAF mutational status
Lakatos, G., Köhne, C., & Bodoky, G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09913-7 · Cited by 31
Kim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 33
Ozawa, S., Miura, T., Terashima, J., & Habano, W. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.82 · Cited by 30
Loree, J. M., Dowers, A., Tu, D., Jonker, D. J., Edelstein, D. L., Quinn, H., Holtrup, F., Price, T. J., Zalcberg, J. R., Moore, M. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2710 · Cited by 30
Xu, X., Ai, L., Hu, K., Liang, L., Lv, M., Wang, Y., Cui, Y., Li, W., Li, Q., Yu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51536-x · Cited by 30
Metadata
- Authors
- Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., Tamburini, E., Barone, C., Masi, G., Pantano, F., Pucci, F., Corsi, D. C., Pella, N., Bergamo, F., Rofi, E., Barbara, C., Falcone, A., & Santini, D.
- Affiliations
- University of Pisa (IT)
- Università Campus Bio-Medico (IT)
- Istituto Oncologico Veneto (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, Pisa, Italy
- University of Udine (IT)
- Ospedale Infermi di Rimini (IT)
- Università Cattolica del Sacro Cuore (IT)
- Ospedale di Parma (IT)
- Fatebenefratelli Hospital (IT)
- Medical Oncology Unit, Presidio Ospedaliero Felice Lotti, Pontedera, Italy
- Corresponding author
- Falcone, Alfredo
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-03-01
- Volume
- 5
- Issue
- 3
- Pages
- 343
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6439839
- OpenAlex
- W2901178367
- Cited by
- 424
- References
- 38
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 75 · 2023: 66 · 2022: 72 · 2021: 61 · 2020: 47 · 2019: 18
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Sanofi
- Celgene
- F. Hoffmann-La Roche
- Merck KGaA
- Eisai
- Università Cattolica del Sacro Cuore
- Servier
- Ipsen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, cetuximab, irinotecan, drug rechallenge, RAS wild-type, BRAF wild-type, acquired resistance, anti-EGFR therapy, circulating tumor DNA, liquid biopsy, third-line therapy, oxaliplatin, bevacizumab, RAS mutations, progression-free survival, overall survival, response rate, disease control rate, predictive biomarkers
- MeSH terms
- Cetuximab, Irinotecan, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Italy, Male, Middle Aged, Prospective Studies, Genes, ras, Risk Factors, Time Factors, Biomarkers, Tumor, Colorectal Neoplasms, Disease Progression, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
